Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1885]

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients...

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine...

Dr Charles E. Geyer - University of Pittsburgh School of Medicine, Pittsburgh...

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer ( Dr Charles E. Geyer - University of Pittsburgh School of Medicine, Pittsburgh, USA )

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource...

Dr Atul Batra - All India Institute Of Medical Sciences Delhi, New Delhi, India

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings ( Dr Atul Batra - All India Institute Of Medical Sciences Delhi, New Delhi, India )

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2−...

Prof Stephen Johnston - The Royal Marsden, London, UK

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer ( Prof Stephen Johnston - The Royal Marsden, London, UK )

MCED blood test demonstrates high specificity, strong predictive value, and...

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer...

Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, USA

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors ( Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, USA )

Enhancing breast cancer care through AI and collaboration

Dr Gabrielle Speijer, Dr Fernando Suarez and Dr Tolga Ozmen

Enhancing breast cancer care through AI and collaboration ( Dr Gabrielle Speijer, Dr Fernando Suarez and Dr Tolga Ozmen )

Proton vs photon radiotherapy shows similar patient-reported quality of life in...

Dr Shannon MacDonald - Southwest Florida Proton Center, Florida, USA

Proton vs photon radiotherapy shows similar patient-reported quality of life in breast cancer patients ( Dr Shannon MacDonald - Southwest Florida Proton Center, Florida, USA )

Transforming cancer care in India: The Access Cancer Care Initiative

Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran

Transforming cancer care in India: The Access Cancer Care Initiative ( Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran )

The hidden biology of addiction and cancer

Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA

The hidden biology of addiction and cancer ( Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA )

Breast cancer survivorship

Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg

Breast cancer survivorship ( Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg )

More from ecancer